Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Devimistat - Rafael Pharmaceuticals

Drug Profile

Devimistat - Rafael Pharmaceuticals

Alternative Names: 6,8-bis(benzylthio)octanoic-acid; Bylantra; CPI-613®

Latest Information Update: 12 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornerstone Pharmaceuticals; Stony Brook University
  • Developer Case Comprehensive Cancer Center; Cornerstone Pharmaceuticals; IQVIA; National Cancer Institute (USA); Rafael Pharmaceuticals; Wake Forest University School of Medicine
  • Class Antineoplastics; Carboxylic acids; Coenzymes; Fatty acids; Small molecules; Sulfides
  • Mechanism of Action Ketoglutarate dehydrogenase complex inhibitors; Pyruvate dehydrogenase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Burkitt's lymphoma; Acute myeloid leukaemia; Pancreatic cancer; Peripheral T-cell lymphoma; T-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Pancreatic cancer
  • Phase II B-cell lymphoma; Burkitt's lymphoma; Myelodysplastic syndromes; Small cell lung cancer; Solid tumours
  • Phase I/II Cancer
  • Phase I Colorectal cancer; Hodgkin's disease; Non-Hodgkin's lymphoma
  • No development reported Biliary cancer

Most Recent Events

  • 07 Feb 2019 Rafael Pharmaceuticals plans a clinical trial for T-cell lymphoma (Combination therapy)
  • 10 Jan 2019 Devimistat receives Orphan Drug status for Acute myeloid leukaemia (Second-line therapy or greater) in European Union
  • 09 Jan 2019 Efficacy and adverse events data from a phase I trial in Pancreatic cancer released by Rafael Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top